NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Novelion Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Novelion Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Novelion Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Novelion Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2019 is calculated as:
For example, Novelion Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2019 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2019 (Change) | * | Current CPI (Mar. 2019) |
= | 1.693 | / | 106.9792 | * | 106.9792 | |
= | 1.693 |
Current CPI (Mar. 2019) = 106.9792.
Novelion Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
200906 | 0.982 | 90.940 | 1.155 |
200909 | 0.802 | 90.624 | 0.947 |
200912 | 0.996 | 90.703 | 1.175 |
201003 | 1.261 | 91.335 | 1.477 |
201006 | 1.167 | 91.809 | 1.360 |
201009 | 0.831 | 92.362 | 0.963 |
201012 | -3.390 | 92.836 | -3.906 |
201103 | 0.872 | 94.338 | 0.989 |
201106 | 1.255 | 94.654 | 1.418 |
201109 | 0.000 | 95.286 | 0.000 |
201112 | 0.000 | 94.970 | 0.000 |
201203 | 0.000 | 96.155 | 0.000 |
201206 | 0.000 | 96.076 | 0.000 |
201209 | 0.000 | 96.392 | 0.000 |
201212 | 0.000 | 95.760 | 0.000 |
201303 | 0.000 | 97.103 | 0.000 |
201306 | 0.000 | 97.182 | 0.000 |
201309 | 0.000 | 97.419 | 0.000 |
201312 | 0.000 | 96.945 | 0.000 |
201403 | 0.000 | 98.604 | 0.000 |
201406 | 0.000 | 99.473 | 0.000 |
201409 | 0.000 | 99.394 | 0.000 |
201412 | 0.000 | 98.367 | 0.000 |
201503 | 0.000 | 99.789 | 0.000 |
201506 | 0.000 | 100.500 | 0.000 |
201509 | 0.000 | 100.421 | 0.000 |
201512 | 0.000 | 99.947 | 0.000 |
201603 | 0.000 | 101.054 | 0.000 |
201606 | 0.000 | 102.002 | 0.000 |
201609 | 0.000 | 101.765 | 0.000 |
201612 | 1.010 | 101.449 | 1.065 |
201703 | 1.617 | 102.634 | 1.685 |
201706 | 2.197 | 103.029 | 2.281 |
201709 | 1.537 | 103.345 | 1.591 |
201712 | 2.084 | 103.345 | 2.157 |
201803 | 1.469 | 105.004 | 1.497 |
201806 | 1.701 | 105.557 | 1.724 |
201809 | 1.609 | 105.636 | 1.629 |
201812 | 2.150 | 105.399 | 2.182 |
201903 | 1.693 | 106.979 | 1.693 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Novelion Therapeutics (OTCPK:NVLNF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Novelion Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired Marketwired • 07-05-2019
By Marketwired Marketwired • 09-12-2019
By Marketwired Marketwired • 01-03-2020
By GlobeNewswire GlobeNewswire • 03-31-2019
By Marketwired Marketwired • 08-23-2018
By Marketwired Marketwired • 02-06-2019
By Marketwired Marketwired • 06-01-2018
By Marketwired Marketwired • 08-22-2019
By PRNewswire PRNewswire • 11-12-2018
By Marketwired Marketwired • 08-30-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.